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DOI 10.1016/j.ccr.2010.10.030SUMMARYDiffuse large B cell lymphoma (DLBCL) is a heterogeneous disease composed of at least two distinct
subtypes: germinal center B cell-like (GCB) and activated B cell-like (ABC) DLBCL. These phenotypic
subtypes segregate with largely unique genetic lesions, suggesting the involvement of different pathogenetic
mechanisms. In this report we show that the BLIMP1/PRDM1 gene is inactivated by multiple mechanisms,
including homozygous deletions, truncating ormissensemutations, and transcriptional repression by consti-
tutively active BCL6, in 53% of ABC-DLBCL. In vivo, conditional deletion of Blimp1 in mouse B cells
promotes the development of lymphoproliferative disorders recapitulating critical features of the human
ABC-DLBCL. These results demonstrate that BLIMP1 is a bona fide tumor-suppressor gene whose loss
contributes to lymphomagenesis by blocking plasma cell differentiation.INTRODUCTION
Diffuse large B cell lymphoma (DLBCL) represents the most
common type of non-Hodgkin’s lymphoma in the adult,
accounting for 40% of all diagnoses (Abramson and Shipp,
2005). Based on gene expression profile analysis, distinct
DLBCL subtypes have been identified whose transcriptional
programs resemble that of normal B cells at various stages of
differentiation (Alizadeh et al., 2000; Shaffer et al., 2002a). These
include the germinal center B cell-like (GCB) DLBCL, presum-
ably derived from a transformed germinal center (GC) centro-
blast, and the activated B cell-like (ABC) DLBCL, whose cell ofSignificance
ABC-DLBCL, the less curable subtype of DLBCL, has themolec
center B cells undergoing plasma cell differentiation. Our result
inactivated in these tumors by a heterogeneous set of mutuall
inactivation of the master plasma cell regulator BLIMP1. The
mouse promotes DLBCL with features of human ABC-DLBCL
is critically involved in suppressing lymphomagenesis and prov
Mice with B cell-specific deletion of Blimp1 may represent fait
568 Cancer Cell 18, 568–579, December 14, 2010 ª2010 Elsevier Incorigin is less clear but may be related to a plasmablastic B cell.
A third group of DLBCLs is represented by primary mediastinal
large B cell lymphoma, postulated to arise from thymic B cells
(Rosenwald et al., 2003; Savage et al., 2003). A separate classi-
fication, also based on gene expression profiling, identified three
discrete subsets defined by the expression of genes involved in
oxidative phosphorylation (OXP), B cell receptor/proliferation
(BCR), and tumor microenvironment/host inflammatory res-
ponse (HR) (Monti et al., 2005).
The subclassification of DLBCL suggests that this disease
may in fact comprise several distinct entities utilizing different
pathogenetic mechanisms. This notion is supported by theular footprint of a tumor that likely arose from post-germinal
s show that the pathway controlling terminal differentiation is
y exclusive genetic lesions, leading to genetic or epigenetic
observation that conditional B cell deletion of Blimp1 in the
demonstrates that the plasma cell differentiation pathway
ides conclusive evidence forBLIMP1 as a tumor suppressor.
hful models of preclinical interest for this disease.
.
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netic significance segregate with different subtypes of DLBCL
(Lenz et al., 2008b). With a focus on the ABC/GCB-based classi-
fication, it is known that translocations of BCL2 (Huang et al.,
2002), mutations within the BCL6 autoregulatory domain (Iqbal
et al., 2007; Pasqualucci et al., 2003), and mutations of EZH2
(Morin et al., 2010) are associated with the GCB subtype,
whereas BCL6 translocations (Iqbal et al., 2007; Ye et al.,
1993), amplifications of the BCL2 locus on 18q24 (Iqbal et al.,
2004), and mutations within the NF-kB (CARD11, TNFAIP3/
A20) (Compagno et al., 2009; Lenz et al., 2008a) and B cell
receptor signaling (CD79B) (Davis et al., 2010) pathways segre-
gate with the ABC subtype.
Additionally, inactivating mutations of PRDM1/BLIMP1 have
been found exclusively in the ABC subtype (24% of cases)
(Pasqualucci et al., 2006; Tam et al., 2006), although the precise
mechanism by which these lesions contribute to lymphoma
development has not yet been fully elucidated. BLIMP1 encodes
a transcriptional repressor that is essential for the terminal differ-
entiation of all B cells into plasma cells, as demonstrated by the
fact that B cell conditional knockout mice fail to produce plasma
cells and serum immunoglobulins (Shapiro-Shelef et al., 2003).
BLIMP1 is thought to promote terminal differentiation in part by
repressing genes important in B cell receptor signaling and
cellular proliferation (Lin et al., 1997; Shaffer et al., 2002b). Our
initial study also reported rare missense mutations of the
BLIMP1 gene, but their functional consequences were not ad-
dressed. Furthermore, the majority of ABC-DLBCL studied
(77%) did not express the BLIMP1 protein despite the pres-
ence of IRF4, a transcriptional repressor that is known to be
invariably coexpressed with BLIMP1 in normal GC B cells and
in all plasma cells (Angelin-Duclos et al., 2000), suggesting that
mechanisms alternative to mutations may be contributing to
the lack of protein expression in ABC-DLBCL. Finally, in vivo
evidence establishing a direct link between BLIMP1 inactivation
and lymphomagenesis has yet to be reported.
In the present study we investigated the full spectrum of
BLIMP1 lesions by comprehensively characterizing a large panel
of DLBCLs for the presence of mutations, copy number alter-
ations, and expression of the BLIMP1 protein. We analyzed the
functional consequences of the BLIMP1 missense mutations
and explored additional epigenetic mechanisms to inactivate
BLIMP1 in ABC-DLBCL. Finally, we assessed the contribution
of BLIMP1 inactivation to the pathogenesis of ABC-DLBCL
in vivo.
RESULTS
Inactivation of BLIMP1 by Truncating Mutations
and Biallelic Gene Deletions in DLBCL
To investigate the full complement of genetic lesions affecting
BLIMP1 in DLBCL, we characterized 158 DLBCL samples (139
primary biopsies and 19 cell lines) representative of the major
phenotypic subtypes for the presence of mutations and copy
number changes affecting the BLIMP1 gene. The study panel
included 51 ABC, 61 GCB, and 10 unclassified DLBCLs, as
determined by gene expression profile analysis. The remaining
36 cases were classified by immunohistochemistry into GC
(n = 12) and non-GC type (n = 24) (Hans et al., 2004).CanSequencing analysis of theBLIMP1 coding exons identified 18
truncating mutations in 16 biopsies and 2 cell lines, including
frameshift insertions and deletions (n = 11), splice site mutations
(n = 6), and one nonsense mutation. Most of the changes clus-
tered toward the N-terminal portion of the BLIMP1 protein and
were predicted by sequence analysis to inactivate protein func-
tion by removing critical functional domains, including the PR,
proline-rich, and DNA-binding Zinc finger domains (Figure 1A).
Consistent with initial reports (Pasqualucci et al., 2006; Tam
et al., 2006), all of these mutations were found in cases display-
ing an ABC/NC (n = 14/51, 27%) or non-GC (n = 4/24, 17%)
phenotype, indicating that genetic inactivation of BLIMP1 is
specific for this DLBCL subtype (Figure 1B). Analysis of 6q21
deletions, examined by a combination of copy number analyses,
revealed that the majority of the mutated cases (n = 16/18, 89%)
had lost expression of the wild-type allele due to deletion, epige-
netic silencing, or uniparental disomy of the mutated allele,
demonstrating biallelic inactivation of the gene (see Table S1
and Figure S1 available online). Moreover, three ABC-DLBCL
cases were found to harbor biallelic gene deletions of 21 Mb,
742 Kb, and 271 Kb, with the latter only encompassing BLIMP1,
but not the two proximal genes ATG5 and PREP (Figure 1C). This
finding provides direct evidence that BLIMP1 is a critical target
gene in the 6q21-deleted region commonly observed in DLBCL
(Gaidano et al., 1992).
Missense Mutations Affect BLIMP1 Protein Stability
and Its Trans-Repression Activity
In seven additional cases (five ABC/non-GC and two GCB/GC
DLBCLs), we uncovered missense mutations affecting various
residues along the entire BLIMP1 protein (Figure 2A) and associ-
ated with loss of the second allele in three cases (Table S2).
Sequencing analysis of matched normal DNA in one sample
with available material demonstrated the somatic origin of the
mutation (Figure S1). The remaining variants were not found in
public SNP databases (see Experimental Procedures), with
one exception (Y345H), which was, therefore, excluded from
the calculation of the mutation frequency.
In order to test the functional significance of these mutations,
we first assessed the basal expression levels of the correspond-
ing alleles upon transient transfection in 293T cells. As shown in
Figure 2B, three ABC/non-GC DLBCL mutants (P48T, P48R,
and Y149D) were expressed at significantly lower protein levels
compared to wild-type BLIMP1, despite similar mRNA levels,
suggesting that these mutations may destabilize the BLIMP1
protein. Treatment with cycloheximide documented that the
proteins encoded by these three mutants had a significantly
decreased half-life, with the P48R polypeptide being most
unstable (Figure 2C). Accordingly, the Polyphen algorithm
(Sunyaev et al., 2001), used to make in silico predictions of the
potential functional consequences ofmissensemutations, deter-
mined that these three mutations may affect the BLIMP1 protein
structure and/or folding (data not shown). Furthermore, the
SUDHL2ABC-DLBCLcell line,whichharbors theP48Rmutation,
expresses significantly reduced BLIMP1 protein levels despite
elevated amounts ofmRNA (comparable to themultiplemyeloma
cell line U266) (Figure S2), consistent with protein instability.
We then assessed the relative transrepression activity of the
mutant proteins by measuring their ability to downregulate thecer Cell 18, 568–579, December 14, 2010 ª2010 Elsevier Inc. 569
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Figure 1. Inactivation of BLIMP1 by Trun-
cating Mutations and Biallelic Deletions in
ABC-DLBCL
(A) Distribution of truncating mutations along the
BLIMP1 protein, with known functional domains
annotated. Aci, acidic domain; PR, PR domain;
Pro-rich, proline-rich domain (see also Table S1).
(B) Percentage of cases with truncating BLIMP1
mutations in various DLBCL subtypes classified
by gene expression profiling (GEP) or by immuno-
histochemistry (IHC) (see text).
(C) dChip SNP inferred copy number heatmap of
the 6q15-q22.1 region in ABC-DLBCL cases and
three normal DNA controls. Cases harboring
homozygous deletions or truncating mutations
are denoted by symbols (see also Figure S1). The
region indicated by an asterisk is shown at higher
magnification in (D) for the three homozygously
deleted cases (and two normal DNAs), with the
approximate position of the BLIMP1, ATG5, and
PREP genes on the left.
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BLIMP1 as a Tumor Suppressor in B Cell Lymphomaexpression of a luciferase reporter gene driven by a portion
of the CIITA gene promoter, a known BLIMP1 direct target
(Piskurich et al., 2000). Compared to wild type, two mutants
(P48R, C569Y) failed to efficiently repress the reporter (Fig-
ure 2D). In the P48R mutant this effect can be attributed to the
observed protein instability and consequently reduced expres-
sion levels; however, the C569Y mutant had lost its activity
despite comparable protein amounts, suggesting that this muta-
tion may directly impair the BLIMP1 transrepression function.
Indeed, this mutation substitutes a critical cysteine within the
second zinc finger of the BLIMP1 DNA-binding domain, and
abrogated DNA binding to the endogenous CIITA gene
promoter, as assessed in B cells by chromatin immunoprecipita-
tion assays (Figure S2). Overall, these results indicate that
a subset of BLIMP1 missense mutants, specifically those asso-
ciated with ABC/non-GC DLBCL, impairs the stability and/or
function of the BLIMP1 protein.570 Cancer Cell 18, 568–579, December 14, 2010 ª2010 Elsevier Inc.To further investigate the conse-
quences of these mutations in B cells,
we overexpressed the mutant alleles in
the GCB-DLBCL cell line BJAB via lentivi-
ral-mediated transduction. Compared to
empty vector-transduced cells, those in-
fected with wild-type BLIMP1 failed to
proliferate (Figure 3A), consistent with
the previously reported ability of BLIMP1
to repress multiple genes involved in cell
cycle progression (Lin et al., 1997; Shaffer
et al., 2002b). On the contrary, cells in-
fected with vectors expressing either
unstable (P48R, Y149D) or transrepres-
sion defective (C569Y) missense mutants
proliferated at rates similar to those of
control cells. Flow cytometric analysis of
the cell cycle profile revealed a 3-fold
increase in the G0/G1 population of cells
expressing wild-type BLIMP1, but not incells transducedwith the above threemutants (Figure 3B), further
documenting their loss of function.
Consistent with results obtained in the previous assays, the
P48R, Y149D, and C569Y mutants were also unable to repress
the expression of endogenous ID3 and CIITA, two known direct
target genes of BLIMP1 (Shaffer et al., 2002b) (Figure 3C). Interest-
ingly, when compared to cells transduced with wild-type BLIMP1
or other functionally active mutants, cells expressing these three
proteins showed consistently higher levels of GFP, which is core-
gulatedwithBLIMP1via thebicistronic lentiviral cassette, suggest-
ingcounter-selectionagainsthigh, toxic levelsofwild-typeBLIMP1
but not against the functionally deficient mutants (Figure S3).
Finally, we assessed the ability of the various missense
mutants to promote plasma cell differentiation, the primary phys-
iological function of BLIMP1 in B cells. To address this question
we utilized Blimp1 conditional-knockout mouse B cells
(Blimp1CD19KO), which are unable to undergo plasma cell
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Figure 2. Missense Mutations Affect BLIMP1 Protein Stability and Trans-Repression Activity
(A) Distribution of missense mutations along the BLIMP1 protein; in red, mutants that showed an effect in any of the assays performed in (B)–(D) (see also
Table S2).
(B) Western blot (top) and semiquantitative RT-PCR (bottom) analysis of exogenous BLIMP1 expression in 293T cells transfected with equimolar amounts of
vectors expressing HA-tagged wild-type or mutant BLIMP1 alleles.
(C) Analysis of exogenous BLIMP1 protein expression in 293T cells transfected with the indicated mutant alleles and treated with cycloheximide for 2, 4, or 8 hr.
Data were quantitated by densitometric analysis, normalized to b-actin levels, and graphed relative to time zero (top). The Western blot analysis is shown on the
bottom panel.
(D) Transrepression activity of wild-type and mutant BLIMP1 proteins in 293T cells cotransfected with a luciferase reporter construct driven by the human CIITA
promoter (region545 to +123, encompassing a consensus BLIMP1 binding site at position180) (top). Luciferase activities are represented as percent change
relative to the basal activity of the reporter (set to 100), after normalization to Renilla luciferase activity (mean ± SD, as obtained from three independent exper-
iments). In the bottom panel, Western blot analysis using anti-HA antibodies monitors for the corresponding exogenous BLIMP1 expression levels; note that for
the three unstablemutants, higher amounts of plasmid DNAwere transfected to achieve comparable levels. Nevertheless, expression of the P48Rmutant protein
remained significantly lower than wild type, presumably due to its marked instability (see also Figure S2).
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BLIMP1 as a Tumor Suppressor in B Cell Lymphomadifferentiation after stimulation with lipopolysaccharide but can
be rescued by retroviral-mediated delivery of wild-type BLIMP1
(Shapiro-Shelef et al., 2003). In this system approximately 10%
of the cells reconstituted with wild-type BLIMP1 efficiently differ-
entiated into CD138+B220lo plasma cells, analogous to control
cells isolated from wild-type animals (12%) (Figure 3D).CanConversely, plasma cell differentiation was significantly reduced
in cells reconstituted with the P48R and C569Ymutants (5% and
2%, respectively). The Y149D mutant, which was defective in
previous assays, appeared to retain its activity in this system,
likely due to the fact that sufficiently high protein levels were
achieved via retroviral overexpression (data not shown).cer Cell 18, 568–579, December 14, 2010 ª2010 Elsevier Inc. 571
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Figure 3. BLIMP1 Missense Mutations
Impair Its Ability to Induce Cell Cycle Arrest
and Promote Plasma Cell Differentiation
(A) Proliferative capacity of BJAB B cells trans-
duced with lentiviral vectors expressing the indi-
cated BLIMP1 proteins along with GFP, as as-
sessed by an MTT assay on sorted GFP+ cells.
Shown are representative data from one of two
independent experiments performed in duplicate
(mean ± SD) (see also Figure S3).
(B) The left side is the representative flow cytomet-
ric analysis of BJAB B cells transduced with the
indicated vectors and stained for incorporated
BrdU and 7-amino-actinomycin D (7-AAD). Region
gates define cells residing in G0–G1, S, and G2-M
phases of the cell cycle. The G0–G1 population
was quantitated relative to empty vector-trans-
duced cells (set at 1), and the mean ± SD from
two independent experiments is shown below.
(C) Expression of the BLIMP1 targets ID3 and
CIITA in sorted GFP+ BJAB B cells, as determined
by quantitative real-time RT-PCR (n = 3; mean ±
SD). Levels were normalized to both BLIMP1 and
GAPDH and are shown as fold changes relative
to vector-transduced cells (set as 1).
(D) Representative flow cytometric analysis of
CD138 and B220 staining in Blimp1CD19KO splenic
B cells, reconstituted with the indicated vectors
and stimulated to undergo plasma cell differentia-
tion by LPS treatment for 3 days, as compared to
wild-type (Blimp1CD19WT) B cells. The percentage
of cells in the gated (plasma cell) population is
shown. Data from two independent experiments
are quantitated in the bottom panel (mean ± SD).
Mutants that showed an effect in any of the assays
(A–D) are indicated in red.
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BLIMP1 as a Tumor Suppressor in B Cell LymphomaIn summary, data from a variety of assays in both 293T and B
cellsdemonstrate that fourof thesevensomaticmissensemutants
analyzed displayed functional defects, ranging in their severity
from a complete loss of multiple functions (P48R and C569Y) to
more subtle effects (P48T and Y149D). Notably, the defective
mutants were all associated with ABC/non-GC DLBCL cases.
Epigenetic Inactivation of BLIMP1 in ABC-DLBCL Cases
Carrying BCL6 Translocations
Taking together cases with functionally deficient missense
mutants and cases with truncating mutations and biallelic dele-
tions, our data demonstrate that BLIMP1 is genetically inacti-
vated in approximately one-third of ABC-DLBCLs (n = 16/51).
Nonetheless, additional mechanisms appeared to be contrib-
uting to BLIMP1 inactivation in this tumor subtype because an
even larger fraction of cases (n = 27/51, 53%) lacked BLIMP1
protein expression despite the absence of BLIMP1 structural572 Cancer Cell 18, 568–579, December 14, 2010 ª2010 Elsevier Inc.alterations and the presence of IRF4,
a protein invariably coexpressed with
BLIMP1 in a subset of normal human
GC B cells (Angelin-Duclos et al., 2000)
and involved in the terminal differentiation
pathway leading to BLIMP1 activation
(Klein et al., 2006; Saito et al., 2007)(Figures 4A and 4B). Given that the BCL6 transcriptional
repressor can directly repress BLIMP1 expression (Tunyaplin
et al., 2004) and is deregulated by chromosomal translocations
preferentially in ABC-DLBCL (Ye et al., 1995), we assessed the
relationship between structural alterations of BCL6 and BLIMP1.
Notably, 26% (n = 13/51) of ABC-DLBCL cases contained
translocations of BCL6 that were, with two exceptions, mutually
exclusive with BLIMP1 structural alterations (Figure 4C). Cases
with BCL6 translocations also had significantly lower BLIMP1
mRNA levels compared to cases that lacked translocations
and expressed the BLIMP1 protein (Figure S4). Furthermore,
shRNA-mediated knockdown of BCL6 expression in the
BCL6-translocated RCK8 and OCI-Ly8 ABC/non-GC-DLBCL
cell lines promoted upregulation of BLIMP1 mRNA and protein
(Figure 4D; data not shown). Overall, these data support the
hypothesis that deregulated BCL6 expression via chromosomal
translocations is responsible for suppressing BLIMP1
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Figure 4. BCL6 Translocations and BLIMP1
Inactivation Are Mutually Exclusive in ABC-
DLBCL
(A) Immunofluorescence analysis of BLIMP1
(green), IRF4 (red), and CD20 (blue) expression in
normal GC cells of a human tonsil (scale bar,
325 mm; inset, 150 mm).
(B) IRF4 (brown) and BLIMP1 (blue) immunostain-
ing in representative ABC-DLBCL cases display-
ing a normal expression pattern (IRF4+BLIMP1+)
(left panels) or specific lack of BLIMP1 expression
(IRF4+BLIMP1) (right panels) (scale bar, 125 mm).
The percentage of cases in each group is provided
below. Six additional cases (12%) were negative
for expression of both proteins (not shown; see
also Tables S1 and S2 for a detailed characteriza-
tion of individual cases).
(C) Distribution of BLIMP1 and BCL6 structural
alterations in IRF4+ ABC-DLBCL. Columns repre-
sent individual patients, with color codes indi-
cating the presence or absence of the correspond-
ing feature.
(D) BLIMP1 mRNA (left) and protein (right) levels in
the BCL6-translocated RCK8 cell line, transduced
with lentiviral vectors expressing a control shRNA
(shCtrl) or a BCL6-specific shRNA (shBCL6).
BLIMP1 mRNA levels were determined by quanti-
tative real-time RT-PCR and are shown as fold
change relative to shCtrl-transduced cells, after
normalization for GAPDH (n = 3; mean ± SD).
Western blot analysis of BCL6 controls for efficient
BCL6 knockdown (see also Figure S4).
(E) Overall frequency of BLIMP1 and BCL6 struc-
tural alterations in ABC-DLBCL. The unknown
category denotes cases that lack BLIMP1 protein
expression, in the absence of BLIMP1 or BCL6
structural alterations. Two cases carrying both
BCL6 translocations and biallelicBLIMP1 inactiva-
tion were included into the ‘‘BLIMP1 mutation +
deletion’’ category.
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BLIMP1 as a Tumor Suppressor in B Cell Lymphomaexpression in a fraction of IRF4+ ABC-DLBCLs. Thus, over half
(53%, n = 27/51) of these tumors have inactivated BLIMP1
through predominantly mutually exclusive structural alterations
of BLIMP1 and BCL6 (Figure 4E).
Conditional Deletion of Blimp1 in the Mouse Results
in the Development of B Cell Lymphoproliferative
Disorders and DLBCL
To assess the role of BLIMP1 inactivation in lymphomagenesis
in vivo, we generated mice lacking Blimp1 specifically in B cells
by crossing Blimp1 conditional-knockout mice (Ohinata et al.,
2005) with CD19-Cre (Rickert et al., 1997) or Cg1-Cre (Casola
et al., 2006) mice, leading to deletion of Blimp1 in all B cells
(Blimp1CD19KO) or GC B cells (Blimp1Cg1KO), respectively.
Consistent with previous data (Shapiro-Shelef et al., 2003),
Blimp1CD19KO B cells failed to differentiate into immunoglob-
ulin-secreting plasma cells, both in vivo and after ex vivo stimu-
lation (Figure S5; data not shown). On the contrary, immunized
Blimp1Cg1KO mice had selective impairment in GC-derivedCanIgG1, but not in IgM production, consistent with a specific block
in GC-dependent plasma cell differentiation (Figure S5). The
Blimp1CD19KO mice also showed a significant increase of the
fraction of B220+PNAhi GCB cells and CD21+CD23 extra-follic-
ular marginal zone (MZ) B cells (Figure 5A). Although we cannot
formally exclude that a decrease in the CD23+CD21 follicular
(FO) B cell compartment can contribute to the increase in the
MZ B cell fraction, the observation that FO B cell development
is normal in an analogous Blimp1 knockout model (Shapiro-She-
lef et al., 2003) suggests that the accumulation of both GC and
MZ B cells is due to a block in terminal B cell differentiation.
Macroscopic examination of animals sacrificed between 10
and 16 months of age showed the presence of splenomegaly,
suggestive of lymphoproliferation, in most Blimp1CD19KO mice
(90%, n = 34/38) (Figure 5B). Subsequent histological examina-
tion of the lymphoid organs revealed that 68% (n = 26/38) of
the animals had developed a variety of lymphoproliferative disor-
ders, including MZ B cell hyperplasia (MZBCH; n = 14), charac-
terized by the expansion of small cells surrounding the B cellcer Cell 18, 568–579, December 14, 2010 ª2010 Elsevier Inc. 573
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Figure 5. Blimp1 B Cell Conditional
Knockout Mice Develop Lymphoprolifera-
tive Disorders
(A) Representative flow cytometric analysis of
splenic B cell suspensions isolated from mice of
the indicated genotypes and stained for CD21/
CD23 (top) and B220/PNA (bottom). A significant
increase in both GC (B220+PNAhi) and extra-follic-
ular, MZ (CD21+CD23) B cell subpopulations can
be seen in the Blimp1CD19KO animals, as compared
to their control littermates. Data are quantitated on
the right (mean ± SD; n = 3).
(B) Spleen/body weight ratio in mice of the indi-
cated genotypes, analyzed between 10 and
16 months of age. Splenomegaly was defined as
an increase in the spleen/body weight ratio above
0.7% (dashed line). Solid lines indicate the mean
value in each genotype.
(C) Frequency of lymphoproliferative disorders in
the three cohorts shown in (B). p values (Student’s
t test) are provided if significant (<0.05). See also
Figure S5 and Table S3.
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BLIMP1 as a Tumor Suppressor in B Cell Lymphomafollicles; lymphoproliferative disease (LPD) (n = 8), defined by the
initial obliteration of the follicular architecture; and DLBCL (n = 4),
characterized by a complete effacement of the tissue architec-
ture due to infiltrating large cells (Figures 5C and 7). These
disorders were of B cell origin because they stained positive
for the pan-B cell marker B220 (Figure 7). Furthermore, analysis
of the rearranged Ig genes demonstrated a clonal origin of the
disease in all DLBCLs and LPDs tested, as well as in 5/14
(36%) MZBCHs (Figure S6A). Most of the clonal lymphoprolifer-
ations carried somatically hypermutated immunoglobulin genes
(71%, n = 10/14), documenting the tumor derivation from a cell
that had transited the GC (Table S3).
Similar to the Blimp1CD19KO mice, Blimp1Cg1KO mice showed
a 2-fold increase in the proportion of GC B cells after immuniza-
tion (Figure 6A). However, these animals did not display an
increase in the MZ B cell compartment, consistent with the
restriction of Blimp1 deletion to GC B cells. When analyzed574 Cancer Cell 18, 568–579, December 14, 2010 ª2010 Elsevier Inc.between 12 and 18 months of age,
Blimp1Cg1KO mice did not show spleno-
megaly nor increased incidence of
MZBCH, yet they developed LPD and
DLBCL at similar penetrance with respect
to the Blimp1CD19KO model (Figure 6B),
demonstrating that deletion of Blimp1 in
the GC alone was sufficient to promote
lymphomagenesis.
In both models, the majority of the
DLBCLs were Irf4 positive (86%, n = 6/7)
(Figure 7) and negative for GC and differ-
entiation markers (i.e., Bcl6, PNA and
CD138) (Figure S6B), consistent with the
phenotype of a post-GC, activated, pre-
plasmablastic B cell (Falini et al., 2000).
Interestingly, these tumors also displayed
nuclear NF-kB p50 (Figure 7) indicative of
constitutive NF-kB activation, as
observed in human ABC-DLBCL (Daviset al., 2001). Sequencing analysis of three common targets of
genetic lesions associated with constitutive NF-kB activity in
the human disease (Tnfaip3/A20, Card11, and Cd79b) did not
reveal the presence of mutations in six DLBCL cases analyzed
(data not shown), suggesting that constitutive NF-kB activation
is necessary for ABC-DLBCL pathogenesis but is induced by
different mechanisms in this model.
Over time, Blimp1CD19KO mice showed significantly reduced
survival, such that at 15 months of age, only 20% of the animals
were still alive (Figure S6C). Interestingly, the majority of these
mice had an expansion of the bronchus-associated lymphoid
tissue (BALT) (79%, n = 30/38) consistent with the diagnosis of
BALT hyperplasia (BALT-H), in the presence (n = 21/30) or
absence (n = 9/30) of other lymphoproliferative disorders (Fig-
ure S6D). Immunostaining of the BALT-H demonstrated an
expansionofbothPax5+BcellsandCD3+Tcellswithina relatively
preserved B-T cell architecture (Figure S6E), suggestive of
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Figure 6. Conditional Deletion of Blimp1 in
the GC Promotes Lymphomagenesis
(A) Representative flow cytometric analysis of the
CD21+CD23 MZ B cell and B220+PNAhi GC
B cell compartments in mice of the indicated geno-
types, analyzed 10 days after SRBC immunization
(left). Data from three mice per genotype are quan-
titated on the right (mean ± SD).
(B) Percentage of mice developing lymphoprolifer-
ative disorders in the CD19-Cre and Cg1-Cre
models, sacrificed between 10 and 18 months of
age. See also Table S4.
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BLIMP1 as a Tumor Suppressor in B Cell Lymphomaa benign lymphoproliferation. In contrast, Blimp1Cg1KO mice did
not show reduced survival nor suffered from BALT-H (Figures
S6C and S6D), suggesting that the BALT-H results from the
expansion of Blimp1-deleted, extra-follicular mature B cells (see
Table S4 for a comparison of the phenotypes from the two
models). Taken together, these data provide conclusive evidence
forBLIMP1asabonafide tumor suppressor gene inABC-DLBCL.
DISCUSSION
Heterogeneous Mechanisms of BLIMP1 Inactivation
This study demonstrates that BLIMP1 is inactivated in ABC-
DLBCL through a variety of genetic means. In addition to trun-
cating mutations and deletions, we describe a mechanism by
whichmissensemutations inactivate BLIMP1 by either destabiliz-
ing the protein or impairing its transrepression activity. Moreover,
we show that transcriptional silencing of BLIMP1 via deregulating
BCL6 translocations represents an alternative mechanism to
inactivate its function. The mutually exclusive nature of BLIMP1
and BCL6 lesions in DLBCL is consistent with the current model
for plasma cell differentiation, whereby IRF4-mediated transcrip-
tional repression of BCL6 leads to derepression of BLIMP1 and
subsequent GC exit (Klein and Dalla-Favera, 2008; Saito et al.,
2007); thus, structural alterations of either gene should play anal-
ogous roles in blocking terminal differentiation. Moreover, theseCancer Cell 18, 568–579, Dlesions will likely contribute to lymphoma-
genesis through additional, distinct
mechanisms. This possibility is supported
by the fact that the ImHABCL6 mouse
model of DLBCL does not phenocopy
the Blimp1 conditional-knockout mouse
model as the ImHABCL6 mice have both
an increased incidence and heterogeneity
of DLBCL (Cattoretti et al., 2005). Because
BCL6 is known to regulatemultiple cellular
functions, including DNA damage re-
sponses (Phan and Dalla-Favera, 2004;
Ranuncolo et al., 2007, 2008), signal trans-
duction (Basso et al., 2010; Juszczynski
et al., 2009), and cell cycle progression
(Phan et al., 2005; Shaffer et al., 2000), it
is possible that ABC-DLBCL cases
carrying BCL6 lesions have distinct
phenotypic traits.Despite IRF4 expression, one-third of ABC-DLBCLs lacked
BLIMP1 protein expression in the absence of BLIMP1 or BCL6
structural alterations. Analysis of a limited number of cases ruled
out the possibility that BLIMP1 promoter hypermethylation was
responsible for the absence of Blimp1 expression, suggesting
that additional unknown genetic lesionsmay contribute to block-
ing terminal differentiation. In our series, amplification of SPIB or
PAX5, two genes that are also known to repress BLIMP1 (Mora-
Lopez et al., 2007; Schmidlin et al., 2008), did not seem to be
involved (data not shown). However, genome-wide approaches
may be necessary to determine whether structural alterations in
other genes and/or microRNAs, such as those recently
described to regulate BLIMP1 expression (Leucci et al., 2010;
Malumbres et al., 2009; Nie et al., 2008; West et al., 2009; Zhang
et al., 2009), play a role in preventing BLIMP1 protein expression
in this subset.
Association of BLIMP1 Inactivation with Other Lesions
The long latency and the clonality of DLBCL in the Blimp1 condi-
tional-knockout mouse models indicate that oncogenic events
affecting other pathways cooperate with BLIMP1 inactivation
to promote a full neoplastic phenotype and to cause DLBCL.
Because the NF-kB transcriptional complex is known to be
constitutively active in the majority of ABC-DLBCLs, genetic
alterations within this pathway may be important contributorsecember 14, 2010 ª2010 Elsevier Inc. 575
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Figure 7. Blimp1 B Cell Conditional Knockout Mice Develop DLBCL with an Activated Phenotype and Constitutive NF-kB Activation
Representative spleen and lymph node sections from Blimp1 knockout mice presenting with a spectrum of lymphoproliferative disorders, including MZBCH,
LPD, and overt DLBCL, as compared to a wild-type control (see Results for a detailed histological description and Figure S6 for additional data). Tissues
were stained with hematoxylin and eosin (H&E) or immunostained with antibodies against the B220 pan-B cell marker, IRF4, and the NF-kB subunit p50, as indi-
cated. Scale bar, 1250 mm; inset, 125 mm; scale is 50 mm for p50 stain.
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BLIMP1 as a Tumor Suppressor in B Cell Lymphomato lymphomagenesis. Interestingly, concurrent inactivation of
BLIMP1 and mutations within NF-kB pathway components are
found in a significant fraction of human ABC-DLBCLs (data not
shown). Furthermore, the DLBCLs that develop in Blimp1 condi-
tional-knockout mice display evidence of constitutive NF-kB
activation. Thus, future in vivo studies should address the coop-
erative role of these two pathways in lymphomagenesis.
BLIMP1 as a Tumor Suppressor Gene
In the present study, we have provided converging evidence
from human genetics, functional studies, and mouse models
that BLIMP1 is a bona fide tumor suppressor gene in ABC-
DLBCL. One major role for BLIMP1 inactivation in lymphoma-
genesis is to block terminal differentiation and to modulate the
expression of genes involved in cell cycle progression. This
notion is supported by our observation that introduction of
BLIMP1 into a DLBCL cell line leads to G1 cell cycle arrest, as576 Cancer Cell 18, 568–579, December 14, 2010 ª2010 Elsevier Incwell as by previous work showing that activated Blimp1
knockout mouse B cells have increased proliferative capacity
(Shapiro-Shelef et al., 2003). Thus, the expansion of GC and
non-GC MZ B cells observed in our mice may be in part due to
the enhanced proliferation of Blimp1-null activated B cells failing
to undergo terminal differentiation. The Blimp1CD19KO and
Blimp1Cg1KO mice will provide useful preclinical models to
explore additional pathways contributing to lymphomagenesis.EXPERIMENTAL PROCEDURES
Tumor Samples and Classification
Primary biopsies from 139 newly diagnosed patients with DLBCL were ob-
tained from the archives of the Departments of Pathology at Columbia Univer-
sity and Weill Cornell Medical College, after approval by the respective Institu-
tional Review Boards (Exempt Human Subject Research of anonymized/
deidentified existing pathological specimens, under regulatory guideline 45
CFR 46.101(b)(4)). For a description of the 19 DLBCL cell lines used, see.
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BLIMP1 as a Tumor Suppressor in B Cell LymphomaSupplemental Experimental Procedures. Samples were classified by gene
expression profile analysis into the ABC or GCB subtypes as previously
described (Compagno et al., 2009). Cases that could not be profiled due to
the lack of material or low percentage of tumor cells in the biopsy were classi-
fied into GC and non-GC DLBCL based on expression of CD10, BCL6, and
IRF4 (Hans et al., 2004).
Mutational and Copy Number Analyses of the BLIMP1 Gene
Genomic DNA from 158 DLBCL samples was extracted according to standard
methods and used for amplification of the BLIMP1 coding exons as previously
described (Pasqualucci et al., 2006). Purified amplicons were sequenced
directly from both strands and compared to the corresponding germline
sequence (NM_001198) using the Mutation Surveyor Version 2.41 software
(Soft Genetics, State College, PA, USA). Mutations were confirmed on inde-
pendent PCR products, and their somatic origin was verified by analysis of
paired normal DNA, where available. In addition all mutations were verified
in available databases of germline variants (NCBI dbSNP, Build 130; Ensembl;
Watson genome sequence). Copy number analysis of BLIMP1 was performed
using a combination of fluorescent in situ hybridization, single nucleotide poly-
morphism profiling arrays using the Affymetrix Genome-Wide Human SNP
Array 6.0 platform (Affymetrix, Santa Clara, CA, USA), and quantitative copy
number PCR (see Supplemental Experimental Procedures for additional
details).
Transient Transfections/Luciferase Reporter Assays
293T cells were transiently transfected with equimolar amounts (200 ng) of
wild-type and mutant pCMV-HA-BLIMP1 vectors via the calcium phosphate
precipitation method, as described (Gu et al., 1993). For analysis of protein
stability, transfected 293T cells were treated with 50 mg/ml cycloheximide
(Sigma-Aldrich) for 2, 4, and 8 hr before harvesting for protein analysis. For
luciferase reporter assays, 293T cells were cotransfected with 10 ng wild-
type or mutant pCMV-HA-BLIMP1 vectors, 10 ng CIITA-Luc reporter
construct, and 0.1 ng TK-RL Renilla reporter as control for transfection effi-
ciency (Promega, Madison, WI, USA). Cells were harvested 48 hr after trans-
fection, and the Dual Luciferase Reporter Assay (Promega) was performed ac-
cording to the manufacturer’s instructions, in three independent experiments.
Cell Proliferation and Cell Cycle Assays
Cellular proliferation was measured by an MTT assay (Roche) using
10,000 cells/well in duplicate in two independent experiments. To assess
the cell cycle profile, 60 hr after infection with the indicated lentiviral superna-
tants, BJAB cells were labeled with bromodeoxyuridine (BrdU) for 30 min
before harvesting. BrdU incorporation and DNA content were analyzed with
the APC BrdU flow kit (Becton Dickinson) (see Supplemental Experimental
Procedures for a detailed transduction protocol).
BCL6 Knockdown
Apreviously validated BCL6 lentiviral shRNA construct (Basso et al., 2010) was
used to knockdown BCL6 expression in RCK8 B cells. Control and BCL6
shRNA lentiviruses were produced and transduced into RCK8 B cells as
described. Twenty-four hours after the second round of infection, cells were
selected with 1 mg/ml puromycin for 5.5 days, and live cells were purified by
MACS using the Dead Cell Removal Kit (Miltenyi Biotec, Auburn, CA, USA).
Ex Vivo Plasma Cell Differentiation Assay
Primary mouse B cells were purified from the spleen of 8 week old
Blimp1CD19KO mice using the Mouse B cell Isolation Kit (Miltenyi Biotec) and
cultured in RPMI-1640 medium supplemented with 10% fetal calf serum,
100 U/ml penicillin, 100 U/ml streptomycin, 55 mm b-mercaptoethanol, and
10 mg/ml lipopolysaccharides (Sigma-Aldrich). For the complementation
assay, cells were transduced after 1 day with PINCO retroviral vectors ex-
pressing wild-type HA-BLIMP1 or its derivatives, as described. The
percentage of CD138+ B220 plasma cells in the transduced (GFP+) popula-
tion was determined 48 and 72 hr after the second round of infection by flow
cytometric analysis, using anti-CD138-APC (PharMingen, San Jose, CA,
USA) and anti-B220-PerCP (PharMingen) antibodies. As control, splenic B
cells from wild-type mice were treated in parallel with LPS and analyzed for
differentiation 1 day earlier than transduced cells.CanMice
Blimp1CD19KO and Blimp1Cg1KO mice and control littermates were generated
on a mixed C57BL/6:129Sv background by crossing Blimp1fl/+ mice with
Blimp1CD19HET or Blimp1Cg1HET mice respectively, followed by offspring inter-
crossing. Genotyping was performed by PCR analysis, and the protocol is
available upon request. Animals were monitored for tumor incidence and
survival biweekly over a period of 10–18 months and sacrificed for analysis
when visibly ill or at the end of the study, according to protocols approved
by the Columbia University Institutional Animal Care and Use Committee.
Flow cytometric analysis of B and T cell lymphoid compartments and histolog-
ical examination ofmouse tissueswere also performed at 3, 12, and 15months
of age (n = 3–5 mice per genotype). A detailed description of the methods is
available in the accompanying Supplemental Experimental Procedures.
Kaplan-Meier event-free survival curves were generated using the GraphPad
Prism 5 software (GraphPad Sofware, La Jolla, CA, USA), and statistical signif-
icance was calculated using the long-rank (Mantel-Cox) test. The Student’s
t test (unpaired, two-tailed) was used to assess whether differences in the inci-
dence of lymphoproliferative disorders were significant in knockout mice
compared to control wild-type littermates.
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